Lynch syndrome
In a trial of 23 Lynch syndrome patients, those who received the vaccine and developed neoantigen-specific T cells had a higher chance of remaining disease-free over 10 years.
The new Clinical Variant Modeling feature for Invitae's Generation platform showed potential in reducing variants of unknown significance in Lynch syndrome.
South Carolina Genomic Screening Program Strengths, Gaps Revealed in New Analysis
Researchers evaluated the In Our DNA SC population-wide genomic screening effort using an implementation science framework, uncovering effective methods and remaining obstacles.
FDA Grants Marketing Authorization for Invitae Hereditary Cancer DNA Sequencing Test
The Invitae Common Hereditary Cancers Panel is the first test of its kind to obtain FDA marketing authorization, creating an easier pathway for similar tests.
Helix, Nebraska Medicine Partner to Launch Genomic Health-Risk Screening Program
The effort aims to enroll 100,000 people on a voluntary basis, testing genes linked to a higher risk of breast and ovarian cancer, Lynch syndrome, and high cholesterol.